A number of other research firms also recently weighed in on EKF. Panmure Gordon restated a buy rating and issued a GBX 14 ($0.17) price target on shares of Ekf Diagnostics Holding PLC in a research note on Monday, September 5th. FinnCap reaffirmed an under review rating on shares of Ekf Diagnostics Holding PLC in a report on Tuesday, August 30th.
Ekf Diagnostics Holding PLC (LON:EKF) opened at 17.25 on Friday. The stock’s 50 day moving average price is GBX 15.14 and its 200-day moving average price is GBX 13.36. The stock’s market capitalization is GBX 73.96 million. Ekf Diagnostics Holding PLC has a 12-month low of GBX 7.00 and a 12-month high of GBX 23.45.
In other news, insider Mills,Christopher H. B acquired 9,000,000 shares of Ekf Diagnostics Holding PLC stock in a transaction that occurred on Friday, July 15th. The stock was purchased at an average cost of GBX 15 ($0.19) per share, with a total value of £1,350,000 ($1,670,792.08).
Ekf Diagnostics Holding PLC Company Profile
EKF Diagnostics Holdings Plc is focused on the In-Vitro Diagnostic device (IVD) market place. The Company is engaged in the designing, development, manufacture and selling of diagnostic instruments, reagents and certain ancillary products. This activity takes place across various geographical locations which include the United States America, Germany, Poland, Russia, United Kingdom and Ireland.
Receive News & Ratings for Ekf Diagnostics Holding PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekf Diagnostics Holding PLC and related companies with MarketBeat.com's FREE daily email newsletter.